Xeris Pharmaceuticals | XERS - Assets


Xeris Pharmaceuticals reported $370.19M in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
Celltrion KRW 21.08T 530.63B Sep/2025
Cspc Pharmaceutical CNY 46B 1.61B Jun/2025
Dianthus Therapeutics USD 577.44M 251.37M Sep/2025
Divis Laboratories Ltd INR 181.51B 12.19B Sep/2025
Eli Lilly USD 114.94B 14.01B Sep/2025
Kangmei Pharma CNY 13.68B 38.19M Sep/2025
Knight Therapeutics CAD 962.29M 16.93M Sep/2024
Laboratorios Farma EUR 799.88M 99.95M Dec/2023
Malin Corporation EUR 198.5M 70.1M Dec/2024
Medical Developments International AUD 66.4M 1.06M Jun/2025
Neuren Pharmaceuticals AUD 331.25M 78.46M Jun/2025
Organigram Holdings CAD 562.21M 2.4M Sep/2025
Pacira USD 1.3B 239.68M Sep/2025
Perrigo USD 10.08B 10.1M Sep/2025
Pharma Mar EUR 341.66M 6.59M Sep/2025
Qiagen NV USD 6.55B 729.74M Sep/2025
Sartorius EUR 9.61B 413.4M Sep/2025
Sino Biopharmaceutical CNY 74.89B 9.49B Jun/2025
Supernus Pharmaceuticals USD 1.42B 37.35M Sep/2025
Tilray USD 2.07B 1.33B Mar/2025
Zz Pientze Pharmaceu CNY 17.48B 1.23B Sep/2025